Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Holman

Neurological Surgery Houston, TX Medical Doctor

NPI 1386698314 CMS profile 334669

6560 Fannin St, Suite 900, Houston, TX 77030

Open in the dashboard

General payments

$515,680

773 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Holman of Houston, TX is reported in the CMS Open Payments database as having received $515,680 across 773 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $75,352 123
2024 General $23,485 69
2023 General $38,214 93
2022 General $45,819 111
2021 General $166,920 174
2020 General $67,484 87
2019 General $98,405 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Holman
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Paul Holman were reported at $75,352. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Paul Holman Neurological Surgery median Middle half National median
2019 $98,405 $582 $138–$3,006 $163
2020 $67,484 $294 $76–$2,174 $114
2021 $166,920 $387 $105–$2,432 $132
2022 $45,819 $542 $139–$2,989 $149
2023 $38,214 $534 $145–$2,697 $160
2024 $23,485 $574 $155–$3,046 $164
2025 $75,352 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. NuVasive, Inc. $245,629 307 payments
  2. Orthofix Medical, Inc. $77,391 103 payments
  3. Zimmer Biomet Holdings, Inc. $55,226 12 payments
  4. Medtronic, Inc. $36,494 130 payments
  5. Medtronic USA, Inc. $32,747 58 payments
  6. Siemens Medical Solutions USA, Inc. $25,859 19 payments
  7. Bioventus LLC $8,193 3 payments
  8. Medical Device Business Services, Inc. $7,671 3 payments
  9. Globus Medical, Inc. $7,647 7 payments
  10. HD LifeSciences LLC $4,750 1 payment
  11. Other $14,072 130 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $256,521 139 payments
  2. Royalty or License $129,925 7 payments
  3. Travel and Lodging $65,257 217 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $40,044 7 payments
  5. Food and Beverage $23,933 403 payments
Products named General payments · program years 2019–2025
  1. Pulse Spine/Spine Surgery $123,483 72 payments
  2. Timberline $54,925 6 payments
  3. XLIF Spine/Spine Surgery $43,148 57 payments
  4. MISCELLANEOUS $31,016 34 payments
  5. XLIF Spine/Spine Surgery $30,846 82 payments
  6. Pulse Spine/Spine Surgery $16,178 21 payments
  7. O-ARM-ST $14,005 11 payments
  8. MazorX - Renaissance $13,689 18 payments
  9. 7D Surgical System $12,416 8 payments
  10. ALIF $10,702 13 payments
  11. Other $92,621 345 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

81

Median for Neurosurgery: 83

Drug cost

$1,022

Median for Neurosurgery: $872

Branded share of claims

58%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 47 $680
Methocarbamol Generic 14 $200
Methylprednisolone Generic 20 $142

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$284,344

Medicare's payments for the services billed

Medicare patients

332

Average age 74

Services billed

884

200 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 42%
Osteoporosis 42%
Diabetes 31%
Depression 29%
Chronic kidney disease 24%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

773 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record